218 related articles for article (PubMed ID: 25116970)
21. Is concomitant use of methotrexate and oral retinoids dangerous? A review of the data regarding this combination.
Searles AD; Lee AD; Feldman SR
J Am Acad Dermatol; 2011 Apr; 64(4):791-3. PubMed ID: 21414504
[No Abstract] [Full Text] [Related]
22. Methotrexate and other chemotherapeutic agents used to treat psoriasis.
Jeffes EW; Weinstein GD
Dermatol Clin; 1995 Oct; 13(4):875-90. PubMed ID: 8785891
[TBL] [Abstract][Full Text] [Related]
23. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).
Paul C; Puig L; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Lavie F; Mistry S; Bergmans P; Barker J; Reich K;
Br J Dermatol; 2014 Feb; 170(2):425-34. PubMed ID: 24116959
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexate.
Farhangian ME; Feldman SR
Am J Clin Dermatol; 2015 Aug; 16(4):285-294. PubMed ID: 25963062
[TBL] [Abstract][Full Text] [Related]
25. Low dose methotrexate induced asymptomatic keratinocyte dystrophy in a patient of psoriasis vulgaris.
Behera B; Kumari R; Gochhait D; Thappa DM
J Cutan Pathol; 2016 Dec; 43(12):1238-1241. PubMed ID: 27714834
[No Abstract] [Full Text] [Related]
26. Folate with methotrexate: big benefit, questionable cost.
Brownell I; Strober BE
Br J Dermatol; 2007 Jul; 157(1):213. PubMed ID: 17578449
[No Abstract] [Full Text] [Related]
27. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K; Puig L; Paul C; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Brunori M; Mistry S; Bergmans P; Barker J;
Br J Dermatol; 2014 Feb; 170(2):435-44. PubMed ID: 24116868
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
29. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial.
Radmanesh M; Rafiei B; Moosavi ZB; Sina N
Int J Dermatol; 2011 Oct; 50(10):1291-3. PubMed ID: 21950300
[TBL] [Abstract][Full Text] [Related]
30. Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy.
Khopkar U; Bhor U
Indian J Dermatol Venereol Leprol; 2008; 74(4):379-82. PubMed ID: 18797063
[TBL] [Abstract][Full Text] [Related]
31. Methotrexate in the treatment of psoriasis.
Bright RD
Cutis; 1999 Nov; 64(5):332-4. PubMed ID: 10582158
[TBL] [Abstract][Full Text] [Related]
32. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A; Prinz JC; Gottlieb AB; Kingo K; Sofen H; Ruer-Mulard M; Singh V; Pathan R; Papavassilis C; Cooper S;
Br J Dermatol; 2015 Feb; 172(2):484-93. PubMed ID: 25132411
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of plaque psoriasis with self-administered subcutaneous alefacept.
Strober BE
Arch Dermatol; 2005 Dec; 141(12):1602. PubMed ID: 16365271
[No Abstract] [Full Text] [Related]
34. Methotrexate: new therapeutic approaches.
Puig L
Actas Dermosifiliogr; 2014; 105(6):583-9. PubMed ID: 23434058
[TBL] [Abstract][Full Text] [Related]
35. Methotrexate and psoriasis in the era of new biologic agents.
Saporito FC; Menter MA
J Am Acad Dermatol; 2004 Feb; 50(2):301-9. PubMed ID: 14726893
[No Abstract] [Full Text] [Related]
36. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent.
Berends MA; Snoek J; de Jong EM; van de Kerkhof PC; van Oijen MG; van Krieken JH; Drenth JP
Aliment Pharmacol Ther; 2006 Sep; 24(5):805-11. PubMed ID: 16918884
[TBL] [Abstract][Full Text] [Related]
37. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India.
Kaur I; Dogra S; De D; Kanwar AJ
Pediatr Dermatol; 2008; 25(2):184-8. PubMed ID: 18429775
[TBL] [Abstract][Full Text] [Related]
38. Bullous drug eruption in a patient with psoriasis after a test dose of methotrexate.
Sako EY; Famenini S; Wu JJ
J Am Acad Dermatol; 2013 Nov; 69(5):e264-e265. PubMed ID: 24124857
[No Abstract] [Full Text] [Related]
39. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
Naldi L; Griffiths CE
Br J Dermatol; 2005 Apr; 152(4):597-615. PubMed ID: 15840088
[TBL] [Abstract][Full Text] [Related]
40. Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis.
Barland C; Kerdel FA
Arch Dermatol; 2003 Jul; 139(7):949-50. PubMed ID: 12873907
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
